American Journal of Cardiology
Volume 103, Issue 12 , Pages 1710-1715, 15 June 2009

Eligibility of Individuals With Subclinical Coronary Artery Calcium and Intermediate Coronary Heart Disease Risk for Reclassification (from the Framingham Heart Study)

  • Sarah Rosner Preis, ScD, MPH

      Affiliations

    • Center for Population Studies, National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts
  • ,
  • Shih-Jen Hwang, PhD

      Affiliations

    • Center for Population Studies, National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts
  • ,
  • Caroline S. Fox, MD, MPH

      Affiliations

    • Center for Population Studies, National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts
    • Division of Endocrinology, Metabolism, and Diabetes, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts
  • ,
  • Joseph M. Massaro, PhD

      Affiliations

    • Department of Mathematics, Boston University, Boston, Massachusetts
  • ,
  • Daniel Levy, MD

      Affiliations

    • Center for Population Studies, National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts
  • ,
  • Udo Hoffmann, MD, MPH

      Affiliations

    • MGH Cardiac MR PET CT Program, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
  • ,
  • Christopher J. O'Donnell, MD, MPH

      Affiliations

    • Center for Population Studies, National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Massachusetts
    • Cardiology Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts
    • Corresponding Author InformationCorresponding author: Tel: 508-935-3435; fax: 508-626-1262

Received 17 December 2008; received in revised form 15 February 2009; accepted 15 February 2009. published online 27 April 2009.

Coronary artery calcium (CAC) predicts risk for coronary heart disease (CHD) events and perhaps CAC testing may further stratify risk in individuals at intermediate CHD risk. We sought to determine the percentage of participants at intermediate CHD risk who could potentially be reclassified as having a high CHD risk based on the presence of a high CAC score and the prevalence, treatment, and control of CHD risk factors in this group. Framingham Heart Study Offspring and Third Generation cohort participants underwent multidetector computed tomography (n = 3,529, mean age 51 years, 48% women). High CAC was defined as ≥90th age- and gender-specific percentiles based on a healthy reference group or by an absolute modified Agatston score of 100 HU. Prevalence of CHD risk factors (hypertension, hypercholesterolemia, high low-density lipoprotein cholesterol, low high-density lipoprotein cholesterol, smoking, and obesity), their treatment, and control was compared between nondiabetic participants with and without high CAC. Of the 595 participants at intermediate CHD risk, 22% had CAC ≥90th percentile and 39% had CAC ≥100 and could be eligible for reclassification as having a high CHD risk based on the presence of a high CAC score. There were no statistically significant differences in prevalence, treatment, and control of risk factors between those with and without high CAC. In conclusion, prevalence of CHD risk factors did not differ between intermediate-risk participants with and without high CAC. Approximately 25% of intermediate-risk individuals have high CAC scores and may be eligible for reclassification into a higher-risk category.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This work was supported by the National Heart, Lung, and Blood Institute's Framingham Heart Study (Contract No. N01-HC-25195), Framingham, Massachusetts.

PII: S0002-9149(09)00602-X

doi:10.1016/j.amjcard.2009.02.020

American Journal of Cardiology
Volume 103, Issue 12 , Pages 1710-1715, 15 June 2009